Search hospitals > California > Walnut Creek
Diablo Clinical Research, Inc.
Claim this profileWalnut Creek, California 94598
Global Leader in Diabetes
Global Leader in Type 2 Diabetes
Conducts research for Type 1 Diabetes
Conducts research for Obesity
Conducts research for Migraine
192 reported clinical trials
3 medical researchers
Summary
Diablo Clinical Research, Inc. is a medical facility located in Walnut Creek, California. This center is recognized for care of Diabetes, Type 2 Diabetes, Type 1 Diabetes, Obesity, Migraine and other specialties. Diablo Clinical Research, Inc. is involved with conducting 192 clinical trials across 89 conditions. There are 3 research doctors associated with this hospital, such as Mark Christiansen, MD, Helen L Stacey, and Bonnie S. Kimmel.Top PIs
Mark Christiansen, MDDiablo Clinical Research, Inc.7 years of reported clinical research
Studies Obesity
Studies Diabetes
7 reported clinical trials
12 drugs studied
Helen L StaceyDiablo Clinical Research, Inc.3 years of reported clinical research
Studies Obesity
Studies Diabetes
7 reported clinical trials
7 drugs studied
Bonnie S. KimmelDiablo Clinical Research, Inc.1 year of reported clinical research
Studies Obesity
Studies Diabetes
3 reported clinical trials
5 drugs studied
Clinical Trials running at Diablo Clinical Research, Inc.
Obesity
Diabetes
Type 2 Diabetes
Type 1 Diabetes
Flu
Obstructive Sleep Apnea
Chronic Kidney Disease
Cardiovascular Disease
Thyroid Disease
Hypothyroidism
Orforglipron
for Type 2 Diabetes and Obesity
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
Recruiting2 awards Phase 3
BI 456906
for Diabetes and Obesity
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
Recruiting1 award Phase 37 criteria
BI 456906
for Obesity
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
Recruiting1 award Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Diablo Clinical Research, Inc.?
Diablo Clinical Research, Inc. is a medical facility located in Walnut Creek, California. This center is recognized for care of Diabetes, Type 2 Diabetes, Type 1 Diabetes, Obesity, Migraine and other specialties. Diablo Clinical Research, Inc. is involved with conducting 192 clinical trials across 89 conditions. There are 3 research doctors associated with this hospital, such as Mark Christiansen, MD, Helen L Stacey, and Bonnie S. Kimmel.